Autoimmune Diseases  >>  Saphnelo (anifrolumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Saphnelo (anifrolumab) / AstraZeneca
NCT01559090: Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

Completed
2
17
Japan
MEDI-546
AstraZeneca, MedImmune LLC
Systemic Lupus Erythematosus
08/14
02/17
MUSE, NCT01438489 / 2011-004296-36: A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

Checkmark Presentation of data for moderate to severe SLE at ACR 2015
Nov 2015 - Nov 2015: Presentation of data for moderate to severe SLE at ACR 2015
Completed
2
626
US, Europe, RoW
Anifrolumab 300 mg, MEDI-546, Anifrolumab 1000 mg, Placebo
MedImmune LLC
Systemic Lupus Erythematosus
04/15
04/15

Download Options